Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

STAT+: Roche drug sets new standard for KRAS-driven lung cancer 

Дата публикации: 02-07-2026 14:13:27

Biotech's bull market, Vertex's gene therapy expansion, and more news from The Readout

Основное содержимое страницы с новостью.

Biotech’s bull market, Vertex’s gene therapy expansion, and more news from The Readout
Roche HQ SEBASTIEN BOZON/AFP via Getty Images

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hi! As ever, lots going on in the light-speed world of biotech. The sector’s rally is gathering steam, the FDA’s AI flexibility is getting lost in translation, and Democrats lose a seasoned biopharma policymaker. 

But I’m still reeling from that synthetic biology SpudCell Matt Herper wrote about. 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. Meghana Keshavan covers biotech and contributes to The Readout newsletter.

  2. Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1STAT+: PBMs agree to display TrumpRx drug prices09.2714-08-2026
2STAT+: Prime wins Beam arbitration, clearing path to clinic0709-07-2026
3STAT+: Pharma’s drug spending deflection09.1127-07-2026
4STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more0502-07-2026
5STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer05.3310-08-2026
6STAT+: Halfway into the year, biotech is booming5702-07-2026
7STAT+: Pharmalittle: We’re reading about Anthropic drug development goals, Trump drug plan snags, and more0701-07-2026
8Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer015.8801-07-2026
9GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population015.7910-07-2026
10STAT+: U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug0502-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 5. Информативность: 7. Источник: www.statnews.com.